Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5888)	1/15/1999
From: Oliver & Co	Respond to of 6136

"HIV-1 Replication in Patients With Undetectable Plasma Virus Receiving HAART (Research Letter)" Lancet (01/09/99) Vol. 353, No. 9147, P. 119; Natarajan, Ven; Bosche, Marjorie; Metcalf, Julie A.; et al. National Institutes of Health researchers found evidence of HIV-1 replication in 26 patients receiving highly active antiretroviral therapy (HAART) who had sustained plasma HIV-1 levels of less than 50 copies/mL. All of the patients were receiving lamivudine with either zidovudine or stavudine, and all but one took protease inhibitors. Half of the patients were also receiving intermittent interleukin-2. Through the examination of peripheral blood mononuclear cells with highly sensitive nested reverse transcriptase-polymerase chain reaction techniques, the scientists found that all but two of the patients showed cell-associated HIV-1 RNA. HIV-1 RNA was found in the lymph node or rectal biopsies of the other two patients. The authors concluded that "prolonged treatment with HAART does not result in total suppression of viral replication despite suppression of plasma HIV-1 RNA to undetectable levels." They add that further methods to inhibit HIV-1 replication are needed.